CClinicalTrials.gg
Not yet recruitingNCT07508397CTS-US-WEIGHTUpdated Apr 2, 2026

Median Nerve Cross-Sectional Area and Body Weight in Carpal Tunnel Syndrome

An observational study in Carpal Tunnel Syndrome, Entrapment Neuropathies and Median Nerve Compression, sponsored by Kayseri City Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Kayseri City Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
120
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aims to evaluate the diagnostic accuracy of ultrasonographic measurements of the median nerve in patients with Carpal Tunnel Syndrome (CTS). While ultrasound is a common diagnostic tool, various physical factors can influence its results. The researchers will investigate how a patient's absolute body weight and Body Mass Index (BMI) affect the size of the median nerve cross-sectional area across different stages of disease severity. The goal is to determine if absolute body weight plays a 'masking' role that could lead to more precise diagnostic interpretations in clinical practice.

Read the detailed description

Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy, and while electrodiagnostic studies (NCS/EMG) remain the gold standard, ultrasonography (USG) has gained popularity as a non-invasive diagnostic tool. However, the correlation between median nerve cross-sectional area (CSA) and electrophysiological severity can be inconsistent due to anthropometric variations.

In this prospective observational study involving 120 participants, the researchers will perform high-resolution ultrasonographic measurements of the median nerve at the level of the pisiform bone. All patients will undergo standardized nerve conduction studies to be classified into mild, moderate, or severe CTS stages according to AAEM criteria.

The study specifically focuses on the 'masking hypothesis,' which suggests that absolute body weight may have a more significant impact on nerve morphological changes than the ratio-based BMI, particularly during the progression from mild to moderate stages. By analyzing these relationships using non-parametric statistical methods, the study seeks to improve the reliability of USG-based diagnostics in diverse patient populations.

02

Conditions studied

  • Carpal Tunnel Syndrome
  • Entrapment Neuropathies
  • Median Nerve Compression

Keywords

  • Ultrasonography
  • Median Nerve
  • Cross-Sectional Area
  • Body Weight
  • Body Mass Index (BMI)
  • Electromyography
  • Diagnostic Accuracy
  • Physical and Rehabilitation Medicine
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of adult patients who were admitted to the Physical and Rehabilitation Medicine (PMR) outpatient clinic with complaints of hand numbness and tingling. The cohort includes individuals from a diverse range of occupational backgrounds and body compositions to evaluate the impact of anthropometric measurements on median nerve morphology.

Inclusion criteria

  • Patients aged between 18 and 75 years.
  • Clinical diagnosis of Carpal Tunnel Syndrome (CTS) based on symptoms (numbness, tingling, nocturnal pain in the median nerve distribution).
  • Electrophysiological confirmation of CTS according to the American
  • Association of Neuromuscular \& Electrodiagnostic Medicine (AAEM) criteria.
  • Ability to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Secondary causes of CTS (e.g., Diabetes Mellitus, Hypothyroidism, Rheumatoid -Arthritis, Chronic Renal Failure).
  • Coexisting neurological conditions (e.g., Cervical Radiculopathy,
  • Polyneuropathy, Brachial Plexopathy).
  • History of previous wrist surgery, trauma, or local corticosteroid injection within the last 6 months.
  • Pregnancy or lactation.
  • Congenital anatomical variations such as a bifid median nerve or persistent median artery (detected during USG).
04

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • CTS Patient Cohort

    Patients aged 18-65 years who were clinically and electrophysiologically diagnosed with idiopathic Carpal Tunnel Syndrome. This single cohort includes patients across all severity stages (mild, moderate, and severe) to evaluate the relationship between median nerve morphology and anthropometric measurements.

    Diagnostic Test: High-Resolution Ultrasonography and Electrophysiological Evaluation

Interventions

  • Diagnostic testHigh-Resolution Ultrasonography and Electrophysiological Evaluation

    Participants underwent a high-resolution ultrasonographic examination using a high-frequency linear probe to measure the median nerve cross-sectional area (CSA) at the level of the pisiform bone. Subsequently, standardized electrophysiological evaluations (motor distal latency and sensory conduction velocity) were performed to classify CTS severity according to AAEM criteria.

    Also known as: Ultrasonography, Nerve Conduction Studies (NCS)

05

What researchers measure

Primary outcomes

  1. Median Nerve Cross-Sectional Area (CSA)

    The cross-sectional area of the median nerve measured in square millimeters using high-resolution ultrasonography at the level of the pisiform bone. This measurement is the primary tool for morphological evaluation of the nerve.

    Time frame: At the time of enrollment (single measurement)

Secondary outcomes

  1. Electrophysiological Severity Grading

    The reported outcome is a single categorical variable representing CTS severity (Mild, Moderate, or Severe). This severity grade is determined by aggregating multiple standard Nerve Conduction Study (NCS) parameters (such as motor distal latency and sensory conduction velocity) into a single classification based on the established AAEM criteria.

    Time frame: At the time of enrollment (single measurement)

  2. Anthropometric Measurements (Absolute Body Weight and BMI)

    Measurement of the participant's absolute body weight (kg) and Body Mass Index to analyze their respective correlations with median nerve CSA and disease severity stages.

    Time frame: At the time of enrollment

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Cartwright MS, Hobson-Webb LD, Boon AJ, Alter KE, Hunt CH, Flores VH, Werner RA, Shook SJ, Thomas TD, Primack SJ, Walker FO; American Association of Neuromuscular and Electrodiagnostic Medicine. Evidence-based guideline: neuromuscular ultrasound for the diagnosis of carpal tunnel syndrome. Muscle Nerve. 2012 Aug;46(2):287-93. doi: 10.1002/mus.23389. PubMed 22806381 ↗
  • Jablecki CK, Andary MT, Floeter MK, Miller RG, Quartly CA, Vennix MJ, Wilson JR; American Association of Electrodiagnostic Medicine; American Academy of Neurology; American Academy of Physical Medicine and Rehabilitation. Practice parameter: Electrodiagnostic studies in carpal tunnel syndrome [RETIRED]. Report of the American Association of Electrodiagnostic Medicine, American Academy of Neurology, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2002 Jun 11;58(11):1589-92. doi: 10.1212/wnl.58.11.1589. No abstract available. PubMed 12058083 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with other researchers to ensure the confidentiality and privacy of the study participants in accordance with local ethical guidelines and national data protection laws (KVKK). The aggregated results and statistical analyses will be made available through the final publication. Specific requests for data may be evaluated by the Principal Investigator upon reasonable request and institutional approval.

08

Registry details

Key details

Study ID
NCT07508397
Lead sponsor
Kayseri City Hospital
Responsible party
Abdullah Goktug Yazar (Dr. Abdullah Goktug Yazar, Kayseri City Hospital) — Principal investigator
First posted
Apr 2, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Jul 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Apr 2, 2026

Study contacts

Abdullah Goktug Yazar, MD
Contact
dragyazar@gmail.com
+905309731140

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion